Login to Your Account



Other News To Note


Monday, May 9, 2011
Rigel Pharmaceuticals Inc., of South San Francisco, said it will assume development of R343, its inhaled Syk inhibitor for allergic asthma, after New York-based Pfizer Inc. opted to return full rights to the drug. The move followed Pfizer's decision to exit the allergy and respiratory therapeutic R&D area. Rigel will evaluate R343's development to date and expects to design a Phase II trial later this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription